



NEWS RELEASE

Savara to Ring Nasdaq Stock Market Opening Bell on July 23rd

2018-07-23

AUSTIN, Texas, July 23, 2018 (GLOBE NEWSWIRE) -- **Savara Inc.** (Nasdaq:SVRA), an orphan lung disease company, announced today that Rob Neville, CEO of Savara, alongside key members of senior management, company directors, and employees, will ring the Nasdaq Stock Market Opening Bell today, July 23rd 2018. The ceremony, which will take place between 9:15 and 9:30 a.m. ET, will stream live online at <https://new.livestream.com/nasdaq/live>.

"It is an honor to be ringing the Nasdaq Opening Bell, which commemorates almost a decade of dedication by our team in our pursuit of developing medicines for patients suffering from rare lung diseases," said Rob Neville, CEO of Savara. "With two ongoing pivotal clinical trials (IMPALA and AVAIL), a Phase 2a clinical trial in NTM (OPTIMA), and patient enrollment in all our studies proceeding on schedule, we have a number of important clinical trial data readouts expected over the next year. In parallel, we will continue our corporate development activities to follow our vision of growing Savara as a leader in the orphan lung disease therapeutics space."

Social Media

Multimedia features including exclusive content, photo postings, status updates and video of bell ceremonies, are available on Nasdaq's various social media pages, including **Facebook**, **Instagram**, **YouTube**, **Tumblr** and **Twitter**.

About Savara

Savara is an orphan lung disease company. Savara's pipeline comprises: Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor, or GM-CSF, in Phase 3 development for autoimmune pulmonary alveolar proteinosis, or aPAP, and in Phase 2a development for nontuberculous mycobacteria, or NTM, lung infection; and AeroVanc, a Phase 3 stage inhaled vancomycin for treatment of persistent methicillin-resistant *Staphylococcus aureus*, or MRSA, infection in cystic fibrosis, or CF. Savara's strategy involves expanding its pipeline of potentially

best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara's management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com (Twitter: [@SavaraPharma](https://twitter.com/SavaraPharma)).

About Nasdaq

Nasdaq (Nasdaq:NDAQ) is a leading global provider of trading, clearing, exchange technology, listing, information and public company services. Through its diverse portfolio of solutions, Nasdaq enables customers to plan, optimize and execute their business vision with confidence, using proven technologies that provide transparency and insight for navigating today's global capital markets. As the creator of the world's first electronic stock market, its technology powers more than 90 marketplaces in 50 countries, and 1 in 10 of the world's securities transactions. Nasdaq is home to approximately 3,900 total listings with a market value of approximately \$13 trillion. To learn more, visit: <http://business.nasdaq.com>

Forward-Looking Statements

Savara cautions you that statements in this press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," and "will," among others. Such statements include, but are not limited to, statements relating to patient enrollment in all our studies proceeding on schedule, that we have a number of important clinical trial data readouts expected over the next year, that we will continue our corporate development activities to follow our vision of growing Savara as a leader in the orphan lung disease therapeutics space, and Savara's strategy. Savara may not actually achieve any of the matters referred to in such forward-looking statements, and you should not place undue reliance on these forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Savara's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with the outcome of our ongoing clinical trials for our product candidates, the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources for Savara's operations and to conduct or continue planned clinical development programs, the ability to obtain the necessary patient enrollment for our product candidates in a timely manner, the ability to successfully develop our product candidates, the risks associated with the process of developing, obtaining regulatory approval for and commercializing drug candidates such as Molgradex and AeroVanc that are safe and effective for use as human

therapeutics and the timing and ability of Savara to raise additional equity capital as needed to fund continued operations. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of our risks and uncertainties, you are encouraged to review our documents filed with the SEC including our recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Savara undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.

Contacts:

Savara Inc.:

Ioana C. Hone (ir@savarapharma.com)

(512) 961-1891

For IR: Solebury Trout

Gitanjali Jain Ogawa (Gogawa@troutgroup.com)

(646) 378-2949

For Media: Neon Interactive

Patrick Wallace (patrick@neoninteractive.com)

(619) 200-7856